In a cross-over study of acromegaly patients inadequately controlled on octreotide 30 mg, pasireotide was more effective in controlling parameters of acromegaly activity (GH < 2.5 μg/L, normal IGF-1) [10]. This evidence concerns the gene GH1 and acromegaly.